Magen BioSciences Secures $1.8 Million in Seed Investment Round

Strategic Insights -

Magen BioSciences, Inc., a biotechnology company developing agents to promote human skin health, has secured a significant investment from notable venture capital firms. The company has attracted $1.8 million from ARCH Venture Partners, TVM Capital, and Venrock Associates, with participation from Alexandria Real Estate and Lux Capital. This funding round marks a crucial milestone for Magen BioSciences as it accelerates its research and development efforts. The company's well-established board of directors, comprising renowned experts in the field, will play a key role in guiding Magen's growth and strategic direction.

Key Takeaways:

  • Magen BioSciences has secured $1.8 million in a seed investment round co-led by ARCH Venture Partners, TVM Capital, and Venrock Associates.
  • The funding round attracted participation from Alexandria Real Estate and Lux Capital.
  • The company's board of directors includes notable figures such as Steven Gillis, Stephen Hoffman, Rich Aldrich, David Fisher, Phillip Sharp, David Shaw, Christopher Walsh, Christoph Westphal, and Robert Langer.
  • Magen's founding board members and significant investors are among the most respected names in the biotechnology industry.
  • Chris Sharp and others will guide the company's scientific advisory board.
  • Magen BioSciences aims to promote the health and appearance of human skin.

Statistics:

  • $1.8 million: Amount raised in the seed investment round.
  • 6: Number of venture capital firms participating in the funding round.
  • 10: Number of investors and board members with notable backgrounds in the biotechnology industry.
  • $1.8 million represents a significant investment for a biotechnology company at the seed stage.

Sources:

  • World Disease Weekly
  • NewsRx.com
  • Magen BioSciences, Inc.
  • ARCH Venture Partners
  • TVM Capital
  • Venrock Associates
  • Alexandria Real Estate
  • Lux Capital